Publications by authors named "P Alvaro Morales"
The EFSA Panel on Food Additives and Flavourings (FAF Panel) evaluated the safety of the extension of uses of quillaia extract (E 999) as a food additive in food supplements supplied in a solid or liquid form, excluding food supplements for infants and young children. Quillaia extract (E 999) was re-evaluated in 2019 by the EFSA FAF Panel, which derived an acceptable daily intake (ADI) of 3 mg saponins/kg bw per day for E 999, while in 2024 a follow-up of the re-evaluation was published by the FAF Panel, recommending some modifications of the existing EU specifications for quillaia extract (E 999). Currently, quillaia extract (E 999) is authorised in two food categories (FCs) i.
View Article and Find Full Text PDFArticle Synopsis
- - Cancer health disparities among different racial and ethnic groups burden health systems due to unequal access to early detection, treatment, and resources, resulting in worse outcomes and higher costs for advanced care.
- - The study aims to evaluate the effectiveness of using genetic markers from the TruSight™ Hereditary Cancer Panel to assess global ancestry in 116 female cancer patients, comparing it with traditional genome-wide markers.
- - Findings reveal a strong correlation in ancestry inference between the TruSight panel and whole genome sequencing, highlighting a mean genetic ancestry in the Colombian cohort of approximately 45.7% European, 46.2% Native American, and 8.11% African, indicating a promising method for exploring cancer disparities.
Article Synopsis
- The EFSA Panel evaluated the safety of hesperetin dihydrochalcone as a new flavoring substance, determining that it did not require a read-across with other flavonoids in a previous group assessment (FGE.32).
- The Panel found no genotoxicity concerns and anticipated that hesperetin dihydrochalcone would be metabolized to harmless products, despite lacking direct ADME studies for this substance.
- Although a 90-day study indicated potential effects on thyroid hormone levels, these were deemed non-adverse, and exposure estimates for both adults and children showed sufficient safety margins.
Article Synopsis
- The activation of the ubiquitin ligase APC/C by the protein Cdc20 is crucial for proper cell division and preventing cancer.
- Defects in this pathway can lead to genome instability, making it a target for cancer treatment.
- The study identifies new pyrimidinethylcarbamate apcin analogues that effectively inhibit APC/C activity and show increased cytotoxicity towards breast cancer cells compared to existing treatments, while sparing normal cells.